Suppr超能文献

通过慢病毒平台将受调控的多种微小RNA和小干扰RNA递送至原代细胞。

Regulated and multiple miRNA and siRNA delivery into primary cells by a lentiviral platform.

作者信息

Amendola Mario, Passerini Laura, Pucci Ferdinando, Gentner Bernhard, Bacchetta Rosa, Naldini Luigi

机构信息

San Raffaele Telethon Institute for Gene Therapy, Milan, Italy.

出版信息

Mol Ther. 2009 Jun;17(6):1039-52. doi: 10.1038/mt.2009.48. Epub 2009 Mar 17.

Abstract

RNA interference (RNAi) has tremendous potential for investigating gene function and developing new therapies. However, the design and validation of proficient vehicles for stable and safe microRNA (miR) and small interfering RNA (siRNA) delivery into relevant target cells remains an active area of investigation. Here, we developed a lentiviral platform to efficiently coexpress one or more natural/artificial miR together with a gene of interest from constitutive or regulated polymerase-II (Pol-II) promoters. By swapping the stem-loop (sl) sequence of a selected primary transcript (pri-miR) with that of other miR or replacing the stem with an siRNA of choice, we consistently obtained robust expression of the chimeric/artificial miR in several cell types. We validated our platform transducing a panel of engineered cells stably expressing sensitive reporters for miR activity and on a natural target. This approach allowed us to quantitatively assess at steady state the target suppression activity and expression level of each delivered miR and to compare it to those of endogenous miR. Exogenous/artificial miR reached the concentration and activity typical of highly expressed natural miR without perturbing endogenous miR maturation or regulation. Finally, we demonstrate the robust performance of the platform reversing the anergic/suppressive phenotype of human primary regulatory T cells (Treg) by knocking-down their master gene Forkhead Transcription Factor P3 (FOXP3).

摘要

RNA干扰(RNAi)在研究基因功能和开发新疗法方面具有巨大潜力。然而,设计和验证能够稳定、安全地将微小RNA(miR)和小干扰RNA(siRNA)递送至相关靶细胞的有效载体,仍是一个活跃的研究领域。在此,我们开发了一种慢病毒平台,可从组成型或调控型聚合酶II(Pol-II)启动子高效共表达一种或多种天然/人工miR以及一个感兴趣的基因。通过将选定初级转录本(pri-miR)的茎环(sl)序列与其他miR的茎环序列进行交换,或用选定的siRNA替换茎部,我们在多种细胞类型中持续获得了嵌合/人工miR的强劲表达。我们在一组稳定表达miR活性敏感报告基因的工程细胞以及一个天然靶标上验证了我们的平台转导情况。这种方法使我们能够在稳态下定量评估每个递送的miR的靶标抑制活性和表达水平,并将其与内源性miR的活性和水平进行比较。外源性/人工miR达到了高表达天然miR的典型浓度和活性,而不会干扰内源性miR的成熟或调控。最后,我们通过敲低人类初级调节性T细胞(Treg)的主基因叉头转录因子P3(FOXP3),证明了该平台在逆转Treg无反应性/抑制性表型方面的强大性能。

相似文献

1
Regulated and multiple miRNA and siRNA delivery into primary cells by a lentiviral platform.
Mol Ther. 2009 Jun;17(6):1039-52. doi: 10.1038/mt.2009.48. Epub 2009 Mar 17.
2
Human natural Treg microRNA signature: role of microRNA-31 and microRNA-21 in FOXP3 expression.
Eur J Immunol. 2009 Jun;39(6):1608-18. doi: 10.1002/eji.200838509.
3
Targeting nuclear receptors with lentivirus-delivered small RNAs in primary human hepatocytes.
Cell Physiol Biochem. 2014;33(6):2003-13. doi: 10.1159/000362976.
4
Transduction with Lentiviral Vectors Altered the Expression Profile of Host MicroRNAs.
J Virol. 2018 Aug 29;92(18). doi: 10.1128/JVI.00503-18. Print 2018 Sep 15.
5
MiR-568 inhibits the activation and function of CD4⁺ T cells and Treg cells by targeting NFAT5.
Int Immunol. 2014 May;26(5):269-81. doi: 10.1093/intimm/dxt065. Epub 2013 Dec 19.
6
Effects of lentiviral-mediated Foxp1 and Foxq1 RNAi on the hepatocarcinoma cell.
Exp Mol Pathol. 2014 Feb;96(1):1-8. doi: 10.1016/j.yexmp.2013.10.015. Epub 2013 Nov 5.
8
MicroRNA-126 regulates the induction and function of CD4(+) Foxp3(+) regulatory T cells through PI3K/AKT pathway.
J Cell Mol Med. 2013 Feb;17(2):252-64. doi: 10.1111/jcmm.12003. Epub 2013 Jan 10.
10
miR-155 inhibition sensitizes CD4+ Th cells for TREG mediated suppression.
PLoS One. 2009 Sep 24;4(9):e7158. doi: 10.1371/journal.pone.0007158.

引用本文的文献

1
YTHDC1-mediated microRNA maturation is essential for hematopoietic stem cells maintenance.
Cell Death Discov. 2024 Oct 16;10(1):439. doi: 10.1038/s41420-024-02203-z.
3
Current status and future of cancer vaccines: A bibliographic study.
Heliyon. 2024 Jan 11;10(2):e24404. doi: 10.1016/j.heliyon.2024.e24404. eCollection 2024 Jan 30.
4
The transcription factor HIF2α partakes in the differentiation block of acute myeloid leukemia.
EMBO Mol Med. 2023 Nov 8;15(11):e17810. doi: 10.15252/emmm.202317810. Epub 2023 Oct 9.
5
Efficient shRNA-based knockdown of multiple target genes for cell therapy using a chimeric miRNA cluster platform.
Mol Ther Nucleic Acids. 2023 Sep 20;34:102038. doi: 10.1016/j.omtn.2023.102038. eCollection 2023 Dec 12.
6
Novel lentiviral vectors for gene therapy of sickle cell disease combining gene addition and gene silencing strategies.
Mol Ther Nucleic Acids. 2023 Mar 22;32:229-246. doi: 10.1016/j.omtn.2023.03.012. eCollection 2023 Jun 13.
8
IPEX Syndrome: Improved Knowledge of Immune Pathogenesis Empowers Diagnosis.
Front Pediatr. 2021 Feb 22;9:612760. doi: 10.3389/fped.2021.612760. eCollection 2021.
9
Targeting regulatory T cells for improving cancer therapy: Challenges and prospects.
Cancer Rep (Hoboken). 2018 Jun;1(1):e21105. doi: 10.1002/cnr2.1105. Epub 2018 May 15.

本文引用的文献

1
Lentiviral Vector Design for Multiple shRNA Expression and Durable HIV-1 Inhibition.
Mol Ther. 2008 Mar;16(3):557-564. doi: 10.1038/sj.mt.6300382. Epub 2016 Dec 8.
2
Posttranscriptional regulation of miRNAs harboring conserved terminal loops.
Mol Cell. 2008 Nov 7;32(3):383-93. doi: 10.1016/j.molcel.2008.10.013.
3
Pre-miRNA loop nucleotides control the distinct activities of mir-181a-1 and mir-181c in early T cell development.
PLoS One. 2008;3(10):e3592. doi: 10.1371/journal.pone.0003592. Epub 2008 Oct 31.
4
A construct with fluorescent indicators for conditional expression of miRNA.
BMC Biotechnol. 2008 Oct 7;8:77. doi: 10.1186/1472-6750-8-77.
5
Engineering and optimization of the miR-106b cluster for ectopic expression of multiplexed anti-HIV RNAs.
Gene Ther. 2008 Dec;15(23):1536-49. doi: 10.1038/gt.2008.147. Epub 2008 Sep 18.
6
A system for Cre-regulated RNA interference in vivo.
Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):13895-900. doi: 10.1073/pnas.0806907105. Epub 2008 Sep 8.
7
Minimizing variables among hairpin-based RNAi vectors reveals the potency of shRNAs.
RNA. 2008 Sep;14(9):1834-44. doi: 10.1261/rna.1062908. Epub 2008 Aug 12.
9
Expression of shRNA from a tissue-specific pol II promoter is an effective and safe RNAi therapeutic.
Mol Ther. 2008 Sep;16(9):1630-6. doi: 10.1038/mt.2008.144. Epub 2008 Jul 29.
10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验